LEON Nanodrugs (branded as LEON) builds NANO systems, a hardware platform that uses the company’s proprietary FR-JET mixing technology to manufacture nanoparticles at GMP scale. The equipment is aimed at overcoming the production bottlenecks that currently hinder RNA medicines, cancer vaccines, cell and gene therapies, and other personalized treatments. LEON’s technology supports small-batch, rapid-turnaround workflows and allows customers to move from early development to commercial volumes without a full process redesign, reducing operational risk and time-to-market. Investor interest is growing as demand for scalable nanoparticle production rises; the company says customer demand is already “growing” and its systems are “market-ready.” Proceeds from the latest round will fund the global market launch of the NANO platform and expansion of the company’s commercial footprint. Financial details such as revenue or unit shipments were not disclosed, but management emphasized that the fundraising was significantly oversubscribed, indicating strong investor confidence. LEON positions itself at an inflection point, expecting to become a leading provider in the rapidly expanding field of nanoparticle-based therapeutics.

Total raised

$21M

Funding rounds

4

Latest round

Series A

Latest activity

Jul 2015